Hong Kong Patent Granted for RECCE Anti-Infectives
Filed with ASX · · 3 pages · English
Sydney Australia, 27 November 2025: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) a leading developer of a New Class of Synthetic Anti-Infectives, is pleased to announce the Hong Kong Special Administrative Region has formally granted Patent Family 4 for Recce’s Anti-Infectives, expiry 2041. The Hong Kong Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), m
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Positive Efficacy Data for Inhaled R327 in HAP/VAP Model
- Patient Dosing Underway in Ph 3 Indonesia DFI Trial
- Preliminary Final Report
- R327G Highly Effective in Burn Wounds Model
- Recce Signs Debt Facility with Avenue Capital Group
Later from Recce Pharmaceuticals
- RCE Awarded Advanced Overseas Finding up to A$85m
- AUD $5.3m R&D Rebate Received
- Quarterly Activities/Appendix 4C Cash Flow Report
- Recce Enters Second U.S. Department of Defense R&D Agreement
- Appendix 4D and Interim Financial Report
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals